These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

866 related items for PubMed ID: 16406064

  • 1. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
    Case AS, Rocconi RP, Kilgore LC, Barnes MN.
    Gynecol Oncol; 2006 Jun; 101(3):499-502. PubMed ID: 16406064
    [Abstract] [Full Text] [Related]

  • 2. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.
    Schwartzberg LS, Yee LK, Senecal FM, Charu V, Tomita D, Wallace J, Rossi G.
    Oncologist; 2004 Jun; 9(6):696-707. PubMed ID: 15561813
    [Abstract] [Full Text] [Related]

  • 3. Comparison of darbepoetin alfa and epoetin alfa in the management of anemia of critical illness.
    Voils SA, Harpe SH, Brophy GM.
    Pharmacotherapy; 2007 Apr; 27(4):535-41. PubMed ID: 17381380
    [Abstract] [Full Text] [Related]

  • 4. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.
    Cersosimo RJ, Jacobson DR.
    Ann Pharmacother; 2006 Jan; 40(1):58-65; quiz 169-70. PubMed ID: 16332942
    [Abstract] [Full Text] [Related]

  • 5. A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia.
    Schwartzberg L, Shiffman R, Tomita D, Stolshek B, Rossi G, Adamson R.
    Clin Ther; 2003 Nov; 25(11):2781-96. PubMed ID: 14693304
    [Abstract] [Full Text] [Related]

  • 6. A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia.
    Charu V, Saidman B, Ben-Jacob A, Justice GR, Maniam AS, Tomita D, Rossi G, Rearden T, Glaspy J.
    Oncologist; 2007 Oct; 12(10):1253-63. PubMed ID: 17962619
    [Abstract] [Full Text] [Related]

  • 7. Effectiveness of darbepoetin alfa versus epoetin alfa in patients with chemotherapy-induced anemia treated in clinical practice.
    Patton J, Reeves T, Wallace J.
    Oncologist; 2004 Oct; 9(4):451-8. PubMed ID: 15266098
    [Abstract] [Full Text] [Related]

  • 8. A retrospective cohort study to assess the impact of therapeutic substitution of darbepoetin alfa for epoetin alfa in anemic patients with myelodysplastic syndrome.
    Patton JF, Sullivan T, Mun Y, Reeves T, Rossi G, Wallace JF.
    J Support Oncol; 2005 Oct; 3(6):419-26. PubMed ID: 16350429
    [Abstract] [Full Text] [Related]

  • 9. Retrospective observational study of patients with chemotherapy-related anemia receiving erythropoietic agents.
    Mark TL, McKenzie RS, Fastenau J, Piech CT.
    Curr Med Res Opin; 2005 Sep; 21(9):1347-54. PubMed ID: 16197652
    [Abstract] [Full Text] [Related]

  • 10. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial.
    20030125 Study Group TrialUniversity of California Los Angeles School of Medicine, Los Angeles, CA 90095, USA. jglaspy@mednet.ucla.edu, Glaspy J, Vadhan-Raj S, Patel R, Bosserman L, Hu E, Lloyd RE, Boccia RV, Tomita D, Rossi G.
    J Clin Oncol; 2006 May 20; 24(15):2290-7. PubMed ID: 16710026
    [Abstract] [Full Text] [Related]

  • 11. Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia.
    Herrington JD, Davidson SL, Tomita DK, Green L, Smith RE, Boccia RV.
    Am J Health Syst Pharm; 2005 Jan 01; 62(1):54-62. PubMed ID: 15658073
    [Abstract] [Full Text] [Related]

  • 12. The impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa.
    Song X, Long SR, Marder WD, Sullivan SD, Kallich J.
    Ann Pharmacother; 2009 Jul 01; 43(7):1203-10. PubMed ID: 19584392
    [Abstract] [Full Text] [Related]

  • 13. Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial.
    Reed SD, Radeva JI, Daniel DB, Mody SH, Forlenza JB, McKenzie RS, Schulman KA.
    Pharmacoeconomics; 2006 Jul 01; 24(5):479-94. PubMed ID: 16706573
    [Abstract] [Full Text] [Related]

  • 14. Use of erythropoiesis-stimulating agents among chemotherapy patients with hemoglobin exceeding 12 grams per deciliter.
    Nordstrom BL, Luo W, Fraeman K, Whyte JL, Nordyke RJ.
    J Manag Care Pharm; 2008 Jul 01; 14(9):858-69. PubMed ID: 19006442
    [Abstract] [Full Text] [Related]

  • 15. Phase III clinical trials with darbepoetin: implications for clinicians.
    Glaspy J.
    Best Pract Res Clin Haematol; 2005 Jul 01; 18(3):407-16. PubMed ID: 15792914
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of the US Oncology Network's recommended guidelines for therapeutic substitution with darbepoetin alfa 200 microg every 2 weeks in both naïve patients and patients switched from epoetin alfa.
    Thames WA, Smith SL, Scheifele AC, Yao B, Giffin SA, Alley JL.
    Pharmacotherapy; 2004 Mar 01; 24(3):313-23. PubMed ID: 15040644
    [Abstract] [Full Text] [Related]

  • 17. Budget impact analysis of darbepoetin alfa every 3 weeks versus epoetin alfa every week for the treatment of chemotherapy-induced anaemia from a US payer's perspective.
    Rubin RJ, Glaspy JA, Adams JL, Mafilios MS, Wang SM, Viswanathan HN, Kallich JD.
    J Med Econ; 2008 Mar 01; 11(2):199-213. PubMed ID: 19450080
    [Abstract] [Full Text] [Related]

  • 18. A US multicenter, retrospective, observational study of erythropoiesis-stimulating agent utilization in anemic, critically ill patients admitted to the intensive care unit.
    Brophy GM, Sheehan V, Shapiro MJ, Lottenberg L, Scarlata D, Audhya P, ASSESS Study Group and Amgen Inc.
    Clin Ther; 2008 Dec 01; 30(12):2324-34. PubMed ID: 19167591
    [Abstract] [Full Text] [Related]

  • 19. Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis.
    Hoggard J, Crouch T, McMurray S, Levine M, Prathikanti R, Scarlata D, Audhya P.
    Curr Med Res Opin; 2006 Oct 01; 22(10):2023-30. PubMed ID: 17022861
    [Abstract] [Full Text] [Related]

  • 20. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia.
    Boccia R, Malik IA, Raja V, Kahanic S, Liu R, Lillie T, Tomita D, Clowney B, Silberstein P.
    Oncologist; 2006 Apr 01; 11(4):409-17. PubMed ID: 16614237
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.